dr. Mohamed Sallam (PhD)

I am working on developing novel nanobodies capable of crossing the blood-cerebrospinal fluid barrier (BCSFB), with the aim of improving drug delivery to the central nervous system for theranostics applications in cancer and infectious diseases. The BCSFB presents a significant challenge for effective drug delivery to the brain, as it tightly regulates the entry of therapeutic agents. My research focuses on designing nanobodies that can efficiently cross this barrier, particularly for diseases requiring targeted brain therapy.

A key component of my work is the development of innovative polymeric nanoparticles and materials designed for multimodal imaging and treatment. These nanoparticles integrate both diagnostic and therapeutic functions into a single platform, enabling precise and efficient treatment delivery while minimizing side effects. The self-assembled systems I am working on are capable of carrying high payloads, including small molecules, proteins, nucleic acids, and radionuclides, which can be used for targeted therapy and imaging.

The core innovation of my approach lies in the use of a chelate-free and linker-free strategy for nanoparticle construction. This method streamlines the production process and enhances the stability and efficacy of the nanomaterials, avoiding complex conjugation chemistry. By incorporating anti-FOLR1 nanobodies, which facilitate BCSFB crossing, alongside other targeting moieties, I am designing systems with optimal cellular uptake, high targeting specificity, and reduced off-target effects.

Ultimately, my research aims to develop next-generation theranostics platforms that can revolutionize the treatment and diagnosis of brain metastases and other CNS-related diseases, advancing personalized medicine and improving patient outcomes.
 

A seasoned bioengineer with 15 years of professional experience, I specialize in the bioapplication of functional polymeric and inorganic nanoparticles for molecular imaging and theranostics. My expertise encompasses the synthesis and characterization of nanoparticles, surface chemistry optimization, and the development of robust in vitro and in vivo validation strategies for molecular probes.

Throughout my career, I have bridged the disciplines of inorganic chemistry, polymer chemistry, biology, and pharmaceutical sciences to create innovative solutions that advance the fields of diagnostics and therapeutics. My multidisciplinary approach enables me to navigate complex challenges, contributing to the design and development of cutting-edge nanosystems tailored for precision medicine.

I am deeply committed to excellence in research and development, driving progress in molecular imaging technologies and theranostics platforms. My work focuses on the seamless integration of nanoparticle design with biological applications, fostering transformative advancements in healthcare solutions.
 

• Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: knowledge mapping and global standing. Frontiers in oncology 2024, 14, 1397790. (PMID: 39011478).
• PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future? Theranostics 2024, 14 (8), 3043. (PMID: 38855174).
   

• Lab address: Technologiepark-Zwijnaarde 71, 9032 Gent
• Lab Roosmarijn Vandenbroucke
• ScholarGoogle
• Mohamed Sallam is interested to receive invitations for presentations or talks